Akero Therapeutics Inc
AKRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.5B
Close$
$4.52
91.7% downside
Current Fair Value
91.7% downsideOvervalued by 91.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.50 Billion |
|---|---|
| Enterprise Value | $4.32 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.75 |
| Beta | -0.4 |
| Outstanding Shares | 82,008,267 |
Return
| Return on Equity | -30.58% |
|---|---|
| Return on Assets | -29.12% |
| Return on Invested Capital | -31.27% |
Valuation & Multiples
| P/E Ratio | -15.31 |
|---|---|
| PEG | -125.58 |
| Price to Sales | - |
| Price to Book Ratio | 4.97 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -14.44 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 7, 2025
EPS Estimate
$-0.94
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3319▼ 16.98% |
|---|---|
| Total Calls | 1,052,100▼ 38.79% |
| Total Puts | 349,200▼ 59.50% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 111.91%▼ 0.91% |
|---|---|
| Total Invested | $4.34B▼ 11.74% |
| Investors Holding | 287▲ 1.00% |
ESG Score
No data